TrialAlzheimer's research & therapy2025

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.

Jeffrey L Cummings et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.